Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Author Correction: Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
Journal: Nature genetics
Published: February 09, 2026
Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial.
Journal: Journal for immunotherapy of cancer
Published: June 15, 2022
Lenvatinib plus pembrolizumab in patients with either treatment-naive or previously treated metastatic renal cell carcinoma (Study 111/KEYNOTE-146): a phase 1b/2 study.
Journal: The Lancet. Oncology
Published: January 22, 2021
Safety and Clinical Activity of Atezolizumab in Patients with Metastatic Castration-Resistant Prostate Cancer: A Phase I Study.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: May 27, 2020
Cisplatin Therapy Does Not Worsen Renal Function in Severe Antenatal Bartter Syndrome.
Journal: Case reports in nephrology and dialysis
Published: January 06, 2017
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial.
Journal: Lancet (London, England)
Published: November 01, 2016
Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Journal: Cancer
Published: March 31, 2015
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
Journal: Nature genetics
Published: January 18, 2013
Showing 1-8 of 8
Last Updated: 09/26/2026